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Histone modifications and chromatin organization in prostate cancer
Prostate cancer is the most common non cutaneous cancer in American men and the second leading cause of cancer deaths in the USA. According to NCI's SEER Cancer Statistics Review, 192,280 men will have been diagnosed with prostate cancer in the USA in 2009 [1, 101] . Androgens, functioning through androgen receptors (ARs), are essential for the initiation and progression of prostate cancer [2, 3] . Thus, treatment of prostate cancer through the androgenablation therapies has been the pri mary treatment for advanced androgendepend ent prostate cancer (ADPC) for over 40 years. Unfortunately, after prostate cancer has pro gressed to a late stage, it progresses into a fatal castrationresistant disease (CRPC) [4, 5] .
Recent progress in epigenetic studies has had a significant impact on our understanding of mechanisms leading to the onset of pros tate cancer as well as the prognosis, diagno sis and treatment of this disease [6] [7] [8] [9] . Strictly speaking, however, epigenetics is defined as the study of heritable changes in genome func tion that occur without changes to the DNA sequence [10, 11] . In a more broad definition, epigenetics may involve multiple mutually interacting mechanisms, including DNA meth ylation, covalent modifications of histone tails and chromatin reorganization (e.g., nucleo somal remodeling and chromosomal loop ing) (Table 1) [12, 13] . Since DNA methylation is the most wellknown epigenetic mechanism and its function in prostate cancer has been extensively discussed [14, 15] , in this article, we appraise recent progress in histone modifica tions and chromatin reorganization as well as highlight their role in prostatic carcinogenesis. Furthermore, this article also provides a sum mary of recent advances in secondgeneration sequencing based technologies for genomewide profiling of epigenetic alterations.
Technological advances: histone modifications & nucleosome positioning mapping
During the past decade, microarraybased tech nologies have played a major role in genome scale ana lysis of the epigenome. Recently, second generation massively parallel highthroughput sequencing (HTS) technologies, which produce tens to hundreds of millions of reads in a single run, have been used extensively in epigenomic studies. Briefly, HTSbased epigenomic profil ing includes chromatin immunoprecipitation (ChIP) followed by HTS (ChIPseq) ana lysis of histone modifications [16] [17] [18] , DNA meth ylation ana lysis such as bisulfite conversion of either the entire genome (MethylCseq) [19] or a CpG islandenriched partition (reduced repre sentation bisulfite sequencing [RRBS] ) [20] , and micrococcal nuclease (MNase) digestionbased nucleosomal positioning ana lysis [21] .
These HTSbased measurements offer several advantages over hybridizationbased microarray ana lysis. First, it is extremely sensitive. A recent study found that some biologically meaningful Epigenetic mechanisms, including histone modifications, nucleosomal remodeling and chromosomal looping, contribute to the onset and progression of prostate cancer. Recent technical advances significantly increase our understanding of the genome-wide epigenetic regulation of gene expression in prostate cancer. Aberrant genomic distribution and global level of histone modifications, nucleosome repositioning at the gene promoter and enhancer regions, as well as androgen receptor-mediated chromosomal looping may lead to the silencing of tumor suppressor genes and the activation of proto-oncogenes. In addition, androgen receptor-induced chromosomal looping facilitates recurrent gene fusion in prostate cancer. Studies in epigenetic regulation have translational implications in the identification of new biomarkers and the development of new therapies in prostate cancer.
future science group Review Chen, Wang, Wang & Li peaks identified by ChIPseq were obscured when the same experiment was conducted with ChIPchip [22] . Second, it is highly reproduc ible. Sultan et al. showed that the correlation co efficients R 2 reached 0.96 between two tech nical replicates for HTS [23] as compared with a value of 0.73-0.90 for microarray [24] .
We will next discuss ChIPseq in detail as this technique has been widely used in histone modification and nucleosome positioning map ping [16] [17] [18] 25] . The full ChIPseq workflow com prises three steps: the experiment, sequencing and data ana lysis. As illustrated in Figure 1 , the experiment step includes in vivo crosslinking, chromatin isolation, fragmentation using soni cation with outcome fragments approximately 200-600 bp in length, protein-DNA complex immunoprecipitation and reverse crosslinking, and DNA fragment purification. If the ChIP experiment aims to map nucleosome position or histone modification, MNase digestion of chro matin instead of sonication is used to localize histone signals to individual nucleosomes [16, 25] . The data ana lysis step includes quality control, reads mapping [22, 26] , peak calling [27] , target gene identification, consensus motif finding, comparative ana lysis with other ChIPseq data and data integration (for example, with RNA seq or microarray expression data). The ultimate goal of data ana lysis is to present and integrate the data in a biologically meaningful way as well as to generate hypotheses, which can be tested by bench scientists.
Like many other technologies, ChIPseq has its own limits and challenges from both an experimental and ana lysis point of view. In the experiment stage, for instance, there is a bias towards GCrich fragments in both library preparation and in amplification before and during sequencing [28, 29] . However, even more challenges come at the ana lysis stage. Such chal lenges exist in all current genomewide ChIP techniques, such as ChIPonchip (ChIP on a microarray) and DNA adenine methyltransferase identification (DamID) [30] . The observation of tens of thousands of binding regions in the genome raised the problems of identifying real functional binding sites from all of these candi dates, and the assignment of the binding sites to their target genes. It is possible that only a subset of the binding sites is functional in a specific cell line under the specific experimental condi tions. It is also likely that some binding sites are indeed nonfunctional [30] . In addition, the assignment of a specific binding site to its target gene is not always straightforward. The expedi ent approach to assign binding sites to the near est known gene might give incorrect results in case of longrange regulation and undiscovered genes or alternative upstream promoters. As a result, altering the level of transcription factors in the cell may only affect the expression level of 1-10% of the potential target genes identified by ChIP [31] [32] [33] [34] . Although currently it is not pos sible to accurately link a particular binding site with a specific target gene from a bioinformatics point of view, the recent advent of global chro mosome conformation capture (3C) techniques (HiC and chromatin interaction analysis by pairedend tag sequencing [CHIAPET]) may permit the global assignment of binding sites to their target genes [35, 36] . However, a couple of challenges are associated with these technolo gies. First, the resolution of HiC remains a problem, whereby 10 million paired reads can only provide 1Mb resolution. Second, although HiC is performed at a low DNA concentration to favor intramolecular ligations, random colli sions of DNA fragments may still happen. This will introduce considerable noise into the results and make the ana lysis and interpretation dif ficult. It is possible that CHIAPET may detect more random collisions owing to the enrichment of ligated products on beads.
Histone modifications in prostate cancer
Histones are no longer considered to be simple 'DNApackaging' proteins. They are subject to a large number of posttranslational modifications 
Mechanisms
Epigenetic inheritance Ref.
DNA methylation DNA methylation is clearly propagated through cell division [10, 11] Histone modifications The epigenetic inheritance of a subset of histone modifications (e.g., H3K27 methylation and H3K9 methylation) has been demonstrated. Other H3 and H4 modifications are potentially propagated through the cell cycle [10, 11] Nucleosome positioning Nucleosome positioning is implicated in epigenetic memory [69, 71] Chromosomal looping The discoveries that epigenetic silencing of imprinted genes requires long-range interactions between regulatory elements suggests that chromosomal looping is a potential epigenetic mechanism [82] [83] [84] future science group
Histone modifications & chromatin organization in prostate cancer Review including acetylation, methylation, phosphoryl ation, ubiquitylation, sumoylation, ADP ribo sylation, deimination and proline isomeriza tion [37] . Among these modifications, histone acetylation and methylation are relatively well studied. Accumulating evidence indicates that the status of acetylation and methylation of spe cific lysine or arginine residues play crucial roles in regulating gene expression [37, 38] . In general, histone acetylation is correlated with transcriptional activation and histone deacetylation is linked to gene silencing [39, 40] . For example, the level of acetylated histone H3 (H3Ac) is increased at both the prostate spe cific antigen (PSA) enhancer and promoter upon androgen treatment, paralleling the accumula tion of PSA mRNA levels in the prostate cancer cell line LNCaP [41] [42] [43] . Treatment of LNCaP cells with a histone deacetylase inhibitor tri chostatin (TSA) promotes RNA polymerase II (Pol II) and H3Ac stability on PSA regulatory regions to augment AR transcription [41, 42] . Histone acetylation is mediated by histone acetyltransferases (HAT) [44] , several of which have been characterized as AR coactivators. For instance, CBP and p300 (KAT3A and KAT3B) are recruited to PSA regulatory regions following androgen treatment and enhance ARmediated transcription in LNCaP cells [41, 42] .
In contrast to histone acetylation, his tone methylation on arginine and lysine can be associated with either gene activation or repression [37, 38] . For example, histone H3K9 mono, di and trimethylation (H3K9me1, H3K9me2 and H3K9me3) have been linked to repression of AR target genes in LNCaP cells. Since H3K9me1, H3K9me2 and H3K9me3 are linked to the repression of AR target genes in LNCaP cells, silencing of H3K9 demethyl ases LSD1 (KDM1), JHDM2A (KDM3A) or JMJD2C (KDM4C), will increase the levels of these repressive marks on AR target gene regu latory regions. Thus, the expression AR target genes PSA, TMPRSS2 and NKX 3.1 will be decreased [45] [46] [47] . By contrast, H3K4 mono and dimethylation (H3K4me1 and H3K4me2) are associated with ARmediated gene activation in CRPC cell lines and tissues. H3K4me1 and H3K4me2 are significantly enriched at the AR enhancer of the protooncogene gene UBE2C [48] in CRPC, which leads to AR binding and UBE2C gene expression [49] .
Recent genomewide mapping of histone mod ifications has confirmed some previous findings regarding the functions of specific histone modifi cations. For example, 18 mapped histone acetyla tions are all positively correlated with gene expres sion in human CD4 + T cells [18] . Similarly, H3K4 methylations have a general correlation with gene transcription in CD4 + T cells [16] . Importantly, largescale studies have provided new insight into the relationship of histone modifications and gene transcription. First, while it was well known that H3K4 trimethylation (H3K4me3) Review Chen, Wang, Wang & Li and H3K27 trimethylation (H3K27me3) are associated with gene activation and repression, respectively, some genomic regions in embryonic stem cells and differentiated cells harbor both of these two marks, namely bivalent domains. These domains are correlated with low levels of gene expression [16, [50] [51] [52] . Interestingly, bivalent domains are also found in the primary prostate epithelial cell line EP156T and the prostate cancer cell line PC3. Surprisingly, the bivalent marked genes in these prostate cells are rather active [53] . Second, H3K4me3 is also detected at many silent promoters, suggesting H3K4me3 alone is not sufficient to support active transcription [54, 55] . Third, different cells have different chroma tin signatures of enhancers and promoters. A ChIPonchip ana lysis of H3K4me1, H3K4me2 and H3K4me3 on 44 human loci selected by the Encyclopedia Of DNA Elements (ENCODE) consortium in HeLa cells found that enhancers are marked by H3K4me1, whereas promoters are marked by H3K4me3. In addition, H3K4me2 is present at both enhancer and promoters in vary ing degrees [56] . These findings were recently confirmed at a wholegenome level in several cell lines [57] . By contrast, ChIPseq ana lysis of all three states of H3K4 methylation in CD4 + T cells found that all three states are detected at some enhancers [16, 18] . In LNCaP cells, while H3K4me1 is enriched primarily at enhancers and H3K4me3 is located predominantly at promot ers, H3K4me2 has the most significant overlap with both enhancers and promoters [25] . Fourth, histone modifications create permissive or non permissive chromatin structures for gene activa tion or repression, but histone modification alone is not sufficient to determine geneexpression level [18, 55] .
Increasing evidence suggests that alterations of histone modifications play important roles during prostate tumorigenesis. For example, we recently found that H3K4me1 and H3K4me2 are selectively enriched at the AR enhancers of Mphase cell cycle genes (e.g., UBE2C and CDK1) in CRPC cell models and tissues, facili tating AR upregulation of these cell cycle genes to promote CRPC growth. Overexpression of a specific H3K4me1 and H3K4me2 demethylase KDM1 significantly decreases AR binding [49] . Similarly, another study found that increased H3K4me3 in prostate cancer cells compared with normal prostate cells is correlated with activation of genes involved in cell growth and survival (e.g., FGFR1 and BCL2) [53] .
Since the increased active chromatin marks like H3K4 methylations in prostate cancer facilitate activation of protooncogene and other genes involved in cell growth and survival, it is conceivable that increased repressive histone marks in prostate cancer lead to tumor suppressor gene silencing. Indeed, genomewide mapping of H3K27me3 in prostate cancer cell lines and tis sues revealed that H3K27me3 genomic distribu tion patterns change during prostate cancer pro gression. The specific enrichment H3K27me3 at the promoters of a large number of genes (e.g., tumor suppressor genes GAS2, PIK3CG and ADRB2) in metastatic prostate cancer com pared with localized prostate cancer and normal prostate represses the expression of these genes, leading to prostate cancer cell growth, survival and invasion. This may ultimately cause a poor clinical outcome for prostate cancer patients [58] [59] [60] . Underlying mechanisms of an increased and broadened H3K27me3 genomic distribution in prostate cancer is attributed to overexpres sion of enhancer of zeste 2 (EZH2), a histone methyltransferase with substrate specificity for H3K27 [61] [62] [63] . Consistent with the role of EZH2 in establishing H3K27me3 chromatin marks, downregulation of EZH2 reactivates expres sion of some H3K27me3 target genes, resulting in prostate cancer cell cycle block and apopto sis [59, 63] . Interestingly, a recent study found that overrexpression of EZH2 in many cancer types including prostate cancer is caused by genomic loss of microRNA101. Overexpression of this microRNA decreases the expression of EZH2 and enrichment of H3K27me3 at its target genes promoters, leading to decreased growth of pros tate cancer cells [64] . In summary, these studies suggest that EZH2 may serve as a therapeutic target, whereas overexpression of microRNA101 may have therapeutic benefit in prostate cancer.
In addition to genomic location ana lysis of histone modifications in prostate cancer, immuno histochemistry (IHC) ana lysis of his tone modifications at the level of whole nuclei in prostate cancer tissue specimens has also afforded important insights into the role in alter ations of histone modifications during prostate cancer progression. It has been found that glo bal levels of H3K4me2, H3K4me3 and histone H3 lysine 18 acetylation (H3K18Ac) are inde pendent predictors of prostate carcinoma recur rence in patients with lowgrade tumors [65, 66] . Similarly, the cellular level of H3K9me2 is also associated with disease outcome, with lower levels predicting poorer prognosis in prostate and other cancers [67] . More recently, the global levels of H3K4me1/2/3 and H3K9me1/2/3, as well as H3 and H4 panacetylation have been [68] . In summary, IHC studies of histone modifications suggest that global histone modification expression pattern changes may serve as prognostic markers in prostate cancer.
Chromatin reorganization in prostate cancer
Although epigenetic regulation of gene expres sion mainly include two wellknown mecha nisms, namely DNA methylation and histone modification, the importance of chromatin based processes (e.g., nucleosomal remodeling and chromosome looping) in epigenetic regu lation and maintenance has been increasingly appreciated [69, 70] .
Assembly, mobilization and disassembly of nucleosomes are key aspects of epigenetic regu lation. For example, in normal cells remarkable nucleosome depletion was found in the promoter regions of a hypomethylated tumor suppressor gene MLH1, whereas in cancer cells the inactive hypermethylated MLH1 promoter is associated with nucleosome occupancy in a mitotically her itable fashion. Importantly, DNA demethylation of the MLH1 gene causes nucleosome eviction and transcriptional activation, providing strong evidence that DNA methylationmediated epi genetic silencing of tumor suppressor genes may involve the insertion of nucleosomes into previously vacant positions [71] . In addition to its ability to control transcriptional initiation, nuclesome positioning has a profound effect on transcriptional elongation. A genomewide ana lysis of histone H2A.Z ChIPseq data and methylated DNAseq data in human T cells identified distinct epigenetic peaks of nucleo somes and DNA methylation enriched at both ends (i.e., just downstream of start codons and just upstream of stop codons) of protein cod ing units. Interestingly, elongating Pol II tends to pause near these two epigenetic ends, caus ing a significant reduction in elongation effi ciency [72] . Such an epigenetic inhibition of Pol II elongation may facilitate the inclusion of constitutive exons during RNA splicing [73, 74] . Altogether, these studies suggest that epi genetic regulation of gene expression may require spe cific nucleosome positioning patterns.
Since a growing body of evidence has revealed that nucleosome positioning changes correlate with alterations in gene expression, many studies have been focused on nucleosome positioning around genes, especially at transcription start sites or in the transcribed regions. A more recent study has found that H3K4me2 marked nucleo some positioning at distal AR binding regions plays a critical role in regulating androgen regulated genes (e.g., PSA and TMPRSS2) in prostate cancer cells [25] . In LNCaP cells, where AR is primarily located at distal regions [49, [75] [76] [77] [78] , androgen treatment dismisses a central nucleo some at the AR binding site that is flanked by two wellpositioned H3K4me2marked nucleo somes, leading to AR transcription complex binding and target gene activation. The central nucleosome is more labile than the flanking ones as it contains the H2A.Z variant and a higher A/T content [25] . Although the finding that nucleosome positioning at enhancer regions influences AR activity significantly increases our understanding of how androgen regulates gene expression in prostate cancer cells, at this point it is not known which chromatin remod elers recognize H3K4me2 to cause nuclesome repositioning upon androgen treatment [79] . Addressing this issue in the future will allow understanding upstream regulatory mechanisms of androgenmediated gene expression.
Chromosomal looping affects gene expres sion within the 3D context of nuclear archi tecture [80, 81] . The discovery that epigenetic silencing of imprinted genes requires longrange interactions between regulatory elements sug gests that chromosome looping is a potential novel epigenetic regulatory mechanism [82] [83] [84] . Using a GAL4 knockin approach as well as the 3C technique that is used for detecting loop ing interactions between genes and their dis tal regulatory elements [85] , Murrell et al. have demonstrated that the intrachromosomal inter actions between the differentially methylated regions in the imprinted genes Igf2 and H19 in mice are epigenetically regulated and partition maternal and paternal chromatin into distinct loops. These loops are changeable depend ing on their epigenetic state, enabling Igf2 to move between an active and a silent chromatin domain [83] . Further studies have found that binding of the 11zincfinger protein CTCF is future science group Review Chen, Wang, Wang & Li required for these inherited higherorder chro matin conformation [84] . Importantly, CTCF also recruits polycomb repressive complex 2, leading to allelespecific methylation at lysine 27 of histone H3 (H3K27) and to suppression of the maternal Igf2 promoters [82] . Altogether these studies indicated that higher order chro matin structure exists in an imprinting clus ter, and the chromosomal loops constitute an important element in the epigenetic regulation of imprinted gene expression.
Increasing evidence suggests that chromo somal looping is important in ARmediated gene regulation in prostate cancer. Recent genomewide ChIP ana lysis revealed that most AR binding sites in prostate cancer cells are far away from the promoters of androgen regulated genes [49, [75] [76] [77] [78] . This raised the question as to how these distal AR binding sites communi cate with their target gene promoters. Recent 3C studies in prostate cancer cells supported the formation of chromosomal loops between distal AR binding sites and proximal promoters of a few target genes including PSA, TMPRSS2 and UBE2C [41, 49, 77] . The recently developed genomewide 3C assays (HiC and CHIAPET) will allow us to map ARmediated global looping in the near future [35, 36] .
The role of ARmediated looping in prostate cancer is not limited to the regulation of tar get gene expression. In the past few years, some highfrequency recurrent gene fusions includ ing the TMPRSS2-ETS family were identified in a majority of prostate cancer patients [86, 87] . Interestingly, two recent studies found that the AR is capable of facilitating the formation of gene fusions in prostate cancer cells through inducing chromosomal looping that brings tumor translocation partners into close spa tial proximity, and recruiting genotoxic stress induced enzymes such as activationinduced cytidine deaminase, which contribute to DNA breakage [88, 89] . These studies convincingly challenge the prevalent concept that genomic translocations in cancer are stochastic events and the enrichment of specific translocations is a result of growth advantage selection, but also raises an important question: given that several thousands of AR binding sites have been identi fied from genomewide ChIP ana lysis, why do these genomic translocations only occur in lim ited regions? One possible answer is that specific DNA methylations and histone modifications at particular AR binding sites also contribute to tumor translocations.
Conclusion
Histone modifications, nucleosomal remodeling, and chromosomal looping are important epi genetic mechanisms that regulate gene expression in prostate cancer (Figures 2 & 3) . The change in the repressive histone mark H3K27me3 and the increased expression of H3K27me3 methyltrans ferase EZH2 leads to the silencing of tumor sup pressor genes (e.g., GAS2 and ADRB2), whereas both the genomic position alteration and protein expression of active histone mark H3K4 methyla tion contribute to activation of protooncogene (e.g., UBE2C). Nucleosome repositioning is not only involved in the silencing of tumor suppres sor genes (e.g., MLH1), but also involved in the activation of genes related to prostate cancer pro gression (e.g., PSA and TMPRSS2). ARinduced chromosomal looping is important for AR tar get gene regulation and facilitates recurrent gene fusions in prostate cancer.
Future perspective
Genomewide approaches are now available for assessing histone modification patterns in prostate cancer. Combining genomic maps and IHC ana lysis of histone modifications changes in prostate cancer will allow us to use histone modifications as diagnostic and prognostic Histone modifications & chromatin organization in prostate cancer Review markers in prostate cancer. In addition, future studies should identify more upstream mecha nisms responsible for alterations of histone mod ifications, which will have therapeutic benefit in prostate cancer. Nucleosome repositioning has been implicated in prostate tumorigenesis. A future challenge will be to identify upstream regulators of nucleosome repositioning. Thanks to recent technological advances of global 3C assays, this would allow global identification of direct AR target genes involved in prostate carcinogenesis in the near future. Finally, future studies should integrate global epigenetic ana lysis (e.g., 3C assay, DNA methylation assay, nucleosome positioning mapping and his tone modification mapping) to identify more molecular triggers of genomic translocations in prostate cancer. In summary, future stud ies in epigenetic regulation will have obvious translational implications in the identification of new biomarkers and the development of new therapies in prostate cancer. 
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Executive summary
Technological advances: histone modifications & nucleosome positioning mapping
High-throughput sequencing (HTS)-based measurements offer several advantages over hybridization-based microarray ana lysis. Chromatin immunoprecipitation (ChIP) combined with HTS (ChIP-seq) is a powerful technique to map histone modifications and nucleosome positioning in the genome with some limitations.
Histone modifications in prostate cancer
Histone acetylation is generally correlated with transcriptional activation, whereas some histone methylation on arginine and lysine are associated with gene activation while others are associated with repression. Recent genome-wide mapping of histone modifications have provided new insight into the relationship between histone modifications and gene transcription. Increasing evidence suggests that alterations in both genomic distribution and global level of histone modifications play important roles during prostate tumorigenesis.
Chromatin reorganization in prostate cancer
In addition to DNA methylation and histone modifications, nucleosome repositioning and chromosomal looping are important epigenetic regulation mechanisms. Nucleosome repositioning plays a critical role in the regulation of androgen-stimulated genes in prostate cancer. Chromosomal looping is important for distal binding androgen receptor-mediated gene regulation and facilitates recurrent gene fusions in prostate cancer. 
